Screener
Icahn Enterprises IEP Pharma — Income Loss From Continuing Operations
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Icahn Enterprises in its filing.
Tagged under the XBRL concept us-gaap:IncomeLossFromContinuingOperations.
The source filing: Icahn Enterprises’s 10-Q, filed August 5, 2026.
- Filed
- Aug 4, 2026, 8:00 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001104659-26-090605
| Line item | Investment | Energy | Automotive | Food Packaging | Real Estate | Home Fashion | Pharma | Holding Company | Consolidated |
|---|---|---|---|---|---|---|---|---|---|
| (Loss) income before income tax benefit | (312) | 40 | (14) | (5) | (1) | (2) | (7) | (85) | (386) |
| Income tax (expense) benefit | — | (6) | 4 | (1) | — | — | — | 1 | (2) |
| Net (loss) income | (312) | 34 | (10) | (6) | (1) | (2) | (7) | (84) | (388) |
| Less: net (loss) income attributable to non-controlling interests | (74) | 41 | — | — | — | — | — | — | (33) |
| Net loss attributable to Icahn Enterprises | $(238) | $(7) | $(10) | $(6) | $(1) | $(2) | $(7) | $(84) | $(355) |
| Supplemental information: | |||||||||
| Capital expenditures | — | $43 | $21 | $7 | $9 | — | — | — | $80 |
| Depreciation and amortization | — | $95 | $12 | $5 | $8 | $2 | $2 | — | $124 |
Item 1. Financial Statements (Unaudited)
FAQ
- What is Icahn Enterprises's pharma — income loss from continuing operations?
- Icahn Enterprises (IEP) reported pharma — income loss from continuing operations of -$7M in Q2 2026.
- How has Icahn Enterprises's pharma — income loss from continuing operations changed year-over-year?
- Icahn Enterprises's pharma — income loss from continuing operations decreased by 275.0% year-over-year, from $4M to -$7M.
- What is the long-term trend for Icahn Enterprises's pharma — income loss from continuing operations?
- Over 3 years (2021 to 2025), Icahn Enterprises's pharma — income loss from continuing operations has grown at a 10.1% compound annual growth rate (CAGR), from -$3M to -$4M.
- What does pharma — income loss from continuing operations mean?
- Indicates the net financial result of the Pharma segment's primary business activities, excluding discontinued operations. This figure serves as a primary benchmark for the segment's recurring profitability and operational success. Investors use this to evaluate the sustainability and growth potential of the segment's core business model.
Ask your AI about Icahn Enterprises's pharma — income loss from continuing operations.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude